SHAPERON INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,105 KRW | +9.86% |
|
+5.30% | -44.02% |
| 03-18 | Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel' | CI |
| 2022 | Shaperon Inc. has completed an IPO in the amount of KRW 13.735 billion. | CI |
Business Summary
Sales per Business
| KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Medicines
100.0
%
| 2,000 | 100.0 % | 215 | 100.0 % | -89.24% |
Sales per region
| KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
South Korea
100.0
%
| 2,000 | 100.0 % | 215 | 100.0 % | -89.24% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Yong Sung
CEO | Chief Executive Officer | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 23,071,031 | 17,153,170 ( 74.35 %) | 0 | 74.35 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| -44.02% | 35.09M | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| +5.07% | 22.94B | |
| -12.75% | 22.22B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| -39.94% | 16.87B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- A378800 Stock
- Company Shaperon Inc.